Randomized, Controlled Study Evaluating CERE-110 in Subjects With Mild to Moderate Alzheimer's Disease

Status:	Completed
Conditions:	Alzheimer Disease
Therapuetic Areas:	Neurology
Healthy:	No
Age Range:	Any
Updated:	11/18/2012
Start Date:	September 2009
End Date:	December 2014
Contact:	Sarah Walter, M.P.H.
Email:	swalter@ucsd.edu
Phone:	858-622-5863

A Double-Blind, Placebo-Controlled (Sham Surgery), Randomized, Multicenter Study Evaluating CERE-110 Gene Delivery in Subjects With Mild to Moderate Alzheimer's Disease

The purpose of this study is to evaluate the potential benefits of CERE-110 in the treatment
of Alzheimer's disease. CERE-110 is an experimental drug that is designed to help nerve
cells in the brain function better. CERE-110 uses a virus to transfer a gene that makes
Nerve Growth Factor (NGF), a protein that may make nerve cells in the brain healthier and
protect them from dying. The virus used in CERE-110 does not cause disease in people.
CERE-110 has been carefully studied in laboratory animals and is in the early stages of
being tested in people.

Fifty patients with mild to moderate Alzheimer's disease will participate in this study.
Half of the study subjects will have CERE-110 injected into the brain during a surgical
procedure, while the other half will undergo a "placebo" surgery where no medication will be
injected. All study participants will be followed for at least two years after surgery.

Inclusion Criteria:

- Diagnosis of mild to moderate Alzheimer's disease

- Approved medications for Alzheimer's disease may be taken if the dose has been stable
for 3 months

- A study partner who can attend all study visits

- Good general health

- Medically able to undergo neurosurgery

Exclusion Criteria:

- Significant neurological disease other than Alzheimer's disease

- Significant depression or other psychiatric disorder

- Unstable medical conditions

We found this trial at

sites

Emory University

201 Dowman Dr
Atlanta, Georgia 30303

(404) 727-6123